

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

CLINICAL BENEFIT	☐ MINIMIZE SAFETY RISK OR CONCERN. ☐ MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. ☐ ASSURE APPROPRIATE LEVEL OF CARE. ☐ ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. ☒ ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. ☐ ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective date:	10/1/2026

POLICY

Plasma Exchange (PE)

Plasma exchange (PE) may be considered **medically necessary** for any of the conditions listed below:

AUTOIMMUNE DISEASES

- Severe multiple manifestations of mixed cryoglobulinemia (MC) such as cryoglobulinemic nephropathy, skin ulcers, sensory motor neuropathy, and widespread vasculitis in combination with immunosuppressive treatment;
- Catastrophic antiphospholipid syndrome.

HEMATOLOGIC CONDITIONS

- ABO incompatible hematopoietic progenitor cell transplantation;
- Hyperviscosity syndromes associated with multiple myeloma or Waldenström macroglobulinemia;
- Idiopathic thrombocytopenic purpura (ITP) in emergency situations;
- Thrombotic thrombocytopenic purpura (TTP);
- Atypical hemolytic-uremic syndrome;
- Post transfusion purpura;
- HELLP syndrome of pregnancy (a severe form of preeclampsia, characterized by hemolysis [H], elevated liver enzymes [EL], and low platelet [LP] counts);
- Myeloma with acute renal failure.

NEUROLOGIC CONDITIONS

- Acute inflammatory demyelinating polyneuropathy (Guillain-Barre syndrome; severity grade 1–2 within 2 weeks of onset; severity grade 3–5 within 4 weeks of onset; and children younger than 10 years old with severe Guillain-Barre syndrome);
- Chronic inflammatory demyelinating polyradiculoneuropathy;
- Multiple sclerosis, with acute fulminant central nervous system demyelination;

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

- Neuromyelitis optica;
- Myasthenia gravis in crisis or as part of preoperative preparation;
- Paraproteinemia polyneuropathy; immunoglobulin A and G;
- N-methyl-d-aspartate receptor antibody encephalitis;
- Progressive multifocal leukoencephalopathy associated with natalizumab.

RENAL DISEASES

- Anti-glomerular basement membrane disease (Goodpasture syndrome);
- Antineutrophil cytoplasmic antibody-associated vasculitis (e.g., Wegener granulomatosis) (also known as granulomatosis with polyangiitis [GPA]) with associated renal failure;
- Dense deposit disease with factor H deficiency and/or elevated C3 nephritic factor.

TRANSPLANTATION

- ABO incompatible solid organ transplantation:
 - o Kidney;
 - o Heart (infants);
- Renal transplantation: antibody mediated rejection; human leukocyte antigen desensitization;
- Focal segmental glomerulosclerosis after renal transplant.

Plasma exchange (PE) is considered **investigational** in all other conditions, including, but not limited, to the following:

- ABO- incompatible solid organ transplant: liver;
- Acute disseminated encephalomyelitis;
- Acute inflammatory demyelinating polyneuropathy (Guillain-Barre syndrome) in children younger than 10 years old with mild or moderate forms;
- Acute liver failure;
- Amyotrophic lateral sclerosis;
- Antineutrophil cytoplasmic antibody-associated rapidly progressive glomerulonephritis (Wegener granulomatosis or granulomatosis with polyangiitis (GPA) without renal failure);
- Aplastic anemia;
- Asthma;
- Autoimmune hemolytic anemia; warm autoimmune hemolytic anemia; cold agglutinin disease;
- Chronic fatigue syndrome;
- Coagulation factor inhibitors;
- Cryoglobulinemia; except for severe mixed cryoglobulinemia, as noted above;

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

- Dermatomyositis and polymyositis;
- Focal segmental glomerulosclerosis (other than after renal transplant);
- Heart transplant rejection treatment;
- Hemolytic uremic syndrome typical (diarrheal-related);
- Idiopathic thrombocytopenic purpura, refractory or non-refractory;
- Inclusion body myositis;
- Lambert-Eaton myasthenic syndrome;
- Multiple sclerosis with chronic progressive or relapsing remitting course;
- Mushroom poisoning;
- Myasthenia gravis with anti-MuSK antibodies;
- Overdose and poisoning (other than mushroom poisoning);
- Paraneoplastic syndromes;
- Paraproteinemia polyneuropathy IgM;
- Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections;
- Pemphigus vulgaris;
- Phytanic acid storage disease (Refsum disease);
- POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes);
- Psoriasis;
- Red blood cell alloimmunization in pregnancy;
- Rheumatoid arthritis;
- Sepsis;
- Scleroderma (systemic sclerosis);
- Stiff person syndrome;
- Sydenham's chorea;
- Systemic lupus erythematosus (including systemic lupus erythematosus nephritis);
- Thyrotoxicosis; AND
- Hyperviscosity syndromes with renal failure (other than associated with multiple myeloma or Waldenström macroglobulinemia).

There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure for the above listed indications.

Policy Guidelines

Patients receiving plasma exchange (PE) as a treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) should meet the diagnostic criteria for CIDP, which were established by the American Academy of Neurology. The use of PE in patients with acute, life-threatening complications of chronic autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, may need to be considered on an individual basis. An example

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

of such a situation would be the development of a severe vasculitis, for which it is hypothesized that the use of PE can acutely lower the level of serum autoantibodies until an alternative long-term treatment strategy can be implemented. However, in these situations, the treatment goals and treatment duration with PE need to be clearly established before its initiation; without such treatment goals, the use of an acute short-term course of PE may insidiously evolve to a chronic use of PE with uncertain benefit.

Cross-Reference:

MP 9.053 Hematopoietic Cell Transplantation for Autoimmune Diseases

PRODUCT VARIATIONS

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

DESCRIPTION/BACKGROUND

Terminology

The terms therapeutic apheresis, plasmapheresis, and plasma exchange (PE) are often used interchangeably, but when properly used denote different procedures. The American Society for Apheresis definitions for these procedures are as follows:

Apheresis is a procedure in which blood of the patient or donor is passed through a medical device that separates out one or more components of blood and returns remainder with or without extracorporeal treatment or replacement of the separated component.

Plasmapheresis is a procedure in which blood of a patient, or the donor is passed through a medical device that separates plasma from the other components of blood, and the plasma is removed (i.e., <15% of total plasma volume) without the use of replacement solution.

Plasma exchange is a therapeutic procedure in which blood of the patient is passed through a medical device that separates plasma from other components of blood, the plasma is removed, and it is replaced with a replacement solution such as colloid solution (e.g., albumin and/ or plasma) or a combination of crystalloid/colloid solution.

This evidence review addresses only PE as a therapeutic apheresis procedure.

Plasma Exchange

The rationale for PE is based on the fact that circulating substances, such as toxins or autoantibodies, can accumulate in the plasma. Also, it is hypothesized that removal of these

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

factors can be therapeutic in certain situations. PE is a symptomatic therapy, because it does not remove the source of the pathogenic factors. Therefore, the success of PE depends on whether the pathogenic substances are accessible through the circulation and whether their rate of production and transfer to the plasma component can be adequately addressed by PE. For example, PE can rapidly reduce levels of serum autoantibodies; however, through a feedback mechanism, this rapid reduction may lead to a rebound overproduction of the same antibodies. This rebound production of antibodies is thought to render the replicating pathogenic clone of lymphocytes more vulnerable to cytotoxic drugs; therefore, PE is sometimes used in conjunction with cyclophosphamide.

Applications

Applications of PE can be broadly subdivided into 2 general categories: (1) acute self-limited diseases, in which PE is used to acutely lower the circulating pathogenic substance; and (2) chronic diseases, in which there is ongoing production of pathogenic autoantibodies. Because PE does not address underlying pathology, and, because of the phenomenon of rebound antibody production, its use in chronic diseases has been more controversial than in acute self-limited diseases.

Also, plasmapheresis has been used in the setting of solid organ transplantation. It has been used as a technique to desensitize high-risk patients before transplant and also as a treatment of antibody-mediated rejection reaction occurring after transplant. Before transplant, plasmapheresis has been most commonly used to desensitize patients receiving an ABO mismatched kidney, often in combination with a splenectomy. As a treatment of antibody-mediated rejection, plasmapheresis is often used in combination with intravenous immunoglobulin or anti-CD20 therapy (i.e., rituximab).

Regulatory Status

The U.S. Food and Drug Administration has a compliance program to ensure that source plasma, source leukocytes, and therapeutic exchange plasma for further manufacture into products for human use are safe, pure, potent, and appropriately labeled. The compliance program covers products intended for use both in injectable drug products (e.g., immune globulin, albumin) and noninjectable products (e.g., in vitro devices such as blood bank reagents).

Product code for therapeutic exchange plasma: 57DI-65.

RATIONALE

Summary of Evidence

Data from published studies clinical input and/or guidelines from the American Society for Apheresis support the use of PE for selected autoimmune, hematologic, neurologic, renal, and transplantation conditions.

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

In 2023, the American Society for Apheresis published an updated Ninth Special Issue of Guidelines on the Use of Therapeutic Apheresis in Clinical Practice. The update included new fact sheets, new indications, and changes in category recommendations for existing fact sheets. However, after review of this literature, there were no significant changes to alter the conclusions reached above.

DEFINITIONS

PATHOGENIC means capable of causing or producing a disease.

PLASMA refers to the watery straw-colored fluid part of the lymph and the blood in which the leukocytes, erythrocytes, and platelets are suspended. Plasma is made up of water, electrolytes, proteins, glucose, fats, bilirubin, and gases and is essential for carrying the cellular elements of the blood through circulation, transporting nutrients, maintaining the acid-base balance of the body, and transporting wastes from the tissue.

PROGENITOR CELL refers to a parent cell that gives rise to a distinct cell lineage by a series of cell divisions.

PLATELET refers to the smallest cells in the blood, essential for coagulation and for hemostasis.

DISCLAIMER

Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.

CODING INFORMATION

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Covered when medically necessary:

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

Procedure Codes								
36514								

ICD-10-CM Diagnosis Codes	Description
C88.00	Waldenstrom macroglobulinemia not having achieved remission
C88.01	Waldenstrom macroglobulinemia, in remission
C90.00	Multiple myeloma not having achieved remission
C90.02	Multiple myeloma in relapse
D59.30	Hemolytic-uremic syndrome, unspecified
D59.31	Infection-associated hemolytic-uremic syndrome
D59.32	Hereditary hemolytic-uremic syndrome
D59.39	Other hemolytic-uremic syndrome
D68.61	Antiphospholipid syndrome
D69.11	Glanzmann thrombasthenia
D69.3	Immune thrombocytopenic purpura
D69.51	Posttransfusion purpura
D89.1	Cryoglobulinemia
E88.09	Other disorders of plasma-protein metabolism, not elsewhere classified
G35	Multiple sclerosis
G35.A	Relapsing-remitting multiple sclerosis
G35.B	Primary progressive multiple sclerosis
G35.B0	Primary progressive multiple sclerosis, unspecified
G35.B1	Active primary progressive multiple sclerosis
G35.B2	Non-active primary progressive multiple sclerosis
G35.C	Secondary progressive multiple sclerosis
G35.C0	Secondary progressive multiple sclerosis, unspecified
G35.C1	Active secondary progressive multiple sclerosis
G35.C2	Non-active secondary progressive multiple sclerosis
G35.D	Multiple sclerosis, unspecified
G36.0	Neuromyelitis optica (Devic)
G61.0	Guillan Barre disease
G61.81	Chronic inflammatory demyelinating polyneuritis
G70.00	Myasthenia gravis without (acute) exacerbation
G70.01	Myasthenia gravis with (acute) exacerbation

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

ICD-10-CM Diagnosis Codes	Description
G72.49	Other inflammatory and immune myopathies, not elsewhere classified
M31.0	Hypersensitivity angiitis
M31.10	Thrombotic microangiopathy, unspecified
M31.11	Hematopoietic stem cell transplantation-associated thrombotic microangiopathy [HSCT-TMA]
M31.19	Other thrombotic microangiopathy
M31.31	Wegener's granulomatosis with renal involvement
N00.A	Acute nephritic syndrome with C3 glomerulonephritis
N00.B1	Acute nephritic syndrome with idiopathic immune membranoproliferative glomerulonephritis (ic-mpgn)
N00.B2	Acute nephritic syndrome with secondary immune complex membranoproliferative glomerulonephritis (ic-mpgn)
N00.6	Acute nephritic syndrome with dense deposit disease
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis
N02.B1	Recurrent and persistent immunoglobulin A nephropathy with glomerular lesion
N02.B2	Recurrent and persistent immunoglobulin A nephropathy with focal and segmental glomerular lesion
N02.B3	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranoproliferative glomerulonephritis
N02.B4	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranous glomerulonephritis
N02.B5	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangial proliferative glomerulonephritis
N02.B6	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangiocapillary glomerulonephritis
N02.B9	Other recurrent and persistent immunoglobulin A nephropathy
N02.6	Recurrent and persistent hematuria with dense deposit disease
N03.A	Chronic nephritic syndrome C3 glomerulonephritis
N03.6	Chronic nephritic syndrome with dense deposit disease
N04.A	Nephrotic syndrome with C3 glomerulonephritis
N04.B1	Nephrotic syndrome with idiopathic immune complex membranoproliferative glomerulonephritis (ic-mpgn)
N04.B2	Nephrotic syndrome with secondary immune complex membranoproliferative glomerulonephritis (ic-mpgn)
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

ICD-10-CM Diagnosis Codes	Description
N04.20	Nephrotic syndrome with diffuse membranous glomerulonephritis, unspecified
N04.21	Primary membranous nephropathy with nephrotic syndrome
N04.22	Secondary membranous nephropathy with nephrotic syndrome
N04.29	Other nephrotic syndrome with diffuse membranous glomerulonephritis
N04.6	Nephrotic syndrome with dense deposit disease
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
N05.6	Unspecified nephritic syndrome with dense deposit disease
N26.9	Renal sclerosis, unspecified
O14.20	HELLP syndrome (HELLP), unspecified trimester
O14.22	HELLP syndrome (HELLP), second trimester
O14.23	HELLP syndrome (HELLP), third trimester
O14.24	HELLP syndrome, complicating childbirth
O14.25	HELLP syndrome, complicating the puerperium
T86.11	Kidney transplant rejection
T86.19	Other complication of kidney transplant
T86.21	Heart transplant rejection
T86.298	Other complications of heart transplant

REFERENCES

1. Food and Drug Administration (FDA). Compliance Program Guidance Manual; Chapter 42- Blood and Blood Products. 2016; Accessed August 10,2021.
2. Shumak KH, Rock GA. Therapeutic plasma exchange. *N Engl J Med.* Mar 22 1984;310(12):762-771. PMID 6199669
3. Kronbichler A, Brezina B, Quintana LF, et al. Efficacy of plasma exchange and immunoabsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. *Autoimmun Rev.* Jan 2016;15(1):38-49. PMID 26318215
4. Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. *N Engl J Med.* May 21 1992;326(21):1373-1379. PMID 1569973
5. Danieli MG, Palmieri C, Salvi A, et al. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. *J Clin Apher.* 2002;17(2):72-77. PMID 12210709

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

6. Khatri BO, McQuillen MP, Harrington GJ, et al. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. *Neurology*. Mar 1985;35(3):312-319. PMID 3974889
7. Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. *Neurology*. Sep 1989;39(9):1143-1149. PMID 2549450
8. Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. *Lancet*. Feb 23 1991;337(8739):441-446. PMID 1671468
9. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. *Neurology*. Jun 13 2000;54(11):2176-2178. PMID 10851390
10. Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. *Neurology*. Feb 08 2000;54(3):603-607. PMID 10680790
11. Anderson NE, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration: clinical-immunological correlations. *Ann Neurol*. Oct 1988;24(4):559-567. PMID 3239956
12. Dwosh IL, Giles AR, Ford PM, et al. Plasmapheresis therapy in rheumatoid arthritis. A controlled, double-blind, crossover trial. *N Engl J Med*. May 12 1983;308(19):1124-1129. PMID 6339939
13. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. *N Engl J Med*. May 21 1992;326(21):1380-1384. PMID 1472183
14. Guillaume JC, Roujeau JC, Morel P, et al. Controlled study of plasma exchange in pemphigus. *Arch Dermatol*. Nov 1988;124(11):1659-1663. PMID 3178248
15. Vicari AM, Folli F, Pozza G, et al. Plasmapheresis in the treatment of stiff-man syndrome. *N Engl J Med*. Jun 01 1989;320(22):1499. PMID 2716805
16. Brashear HR, Phillips LH, 2nd. Autoantibodies to GABAergic neurons and response to plasmapheresis in stiff-man syndrome. *Neurology*. Oct 1991;41(10):1588-1592. PMID 1922799
17. Harding AE, Thompson PD, Kocen RS, et al. Plasma exchange and immunosuppression in the stiff man syndrome. *Lancet*. Oct 14 1989;2(8668):915. PMID 2571826
18. Pagano MB, Murinson BB, Tobian AA, et al. Efficacy of therapeutic plasma exchange for treatment of stiff-person syndrome. *Transfusion*. Jul 2014;54(7):1851-1856. PMID 24527774
19. Pham HP, Williams LA, 3rd. Therapeutic plasma exchange in two patients with stiff-person syndrome. *J Clin Apher*. Oct 2016;31(5):493-494. PMID 26407506
20. Rockx MA, Clark WF. Plasma exchange for treating cryoglobulinemia: a descriptive analysis. *Transfus Apher Sci*. Jun 2010;42(3):247-251. PMID 20382569
21. Michael M, Elliott EJ, Craig JC, et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. *Am J Kidney Dis*. Feb 2009;53(2):259-272. PMID 18950913

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

22. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. *N Engl J Med.* Oct 22 2009;361(17):1676-1687. PMID 19846853
23. Yu X, Gan L, Wang Z, et al. Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis. *Int J Clin Pharmacol Ther.* May 2015;53(5):391-397. PMID 25816886
24. Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. *Cochrane Database Syst Rev.* Feb 27 2017;2:Cd001798. PMID 28241090
25. El-Bayoumi MA, El-Refaey AM, Abdelkader AM, et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barre syndrome: a randomized study. *Crit Care.* Jul 11 2011;15(4):R164. PMID 21745374
26. Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. *Cochrane Database Syst Rev.* Aug 25 2015;8(8):CD003906. PMID 26305459
27. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. *Ann Neurol.* Dec 1999;46(6):878-886. PMID 10589540
28. Kohler W, Bucka C, Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. *J Clin Apher.* Dec 2011;26(6):347-355. PMID 22095647
29. Alipour-Faz A, Shojaei M, Peyvandi H. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. *Mar 2017;117(1):245-249. PMID 27530310*
30. Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. *N Engl J Med.* Nov 21 1991;325(21):1482-1486. PMID 1658648
31. Abboud H, Petrak A, Mealy M, et al. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. *Mult Scler.* Feb 2016;22(2):185-192. PMID 25921047
32. Bonnan M, Valentino R, Olindo S, et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. *Mult Scler.* Apr 2009;15(4):487-492. PMID 19324982
33. Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. *Arch Ophthalmol.* Jul 2012;130(7):858-862. PMID 22776923
34. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. *Ann Neurol.* Feb 2016;79(2):206-216. PMID 26537743
35. Ipe TS, Pham HP, Williams LA, 3rd. Critical updates in the 7th edition of the American Society for Apheresis guidelines. *J Clin Apher.* Jun 27 2017. PMID 28653762
36. DeSena AD, Noland DK, Matevosyan K, et al. Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-D-aspartate receptor antibody encephalitis: A retrospective review. *J Clin Apher.* Aug 2015;30(4):212-216. PMID 25664728

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

37. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. *Neurology*. Feb 03 2009;72(5):402-409. PMID 19188571
38. Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. *Am J Kidney Dis*. Jun 1988;11(6):449-464. PMID 3287904
39. Cole E, Cattran D, Magil A, et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. *Am J Kidney Dis*. Sep 1992;20(3):261-269. PMID 1519607
40. Walsh M, Catapano F, Szpirt W, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. *Am J Kidney Dis*. Apr 2011;57(4):566-574. PMID 21194817
41. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol*. Jul 2007;18(7):2180-2188. PMID 17582159
42. Walsh M, Casian A, Flossmann O, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. *Kidney Int*. Aug 2013;84(2):397-402. PMID 23615499
43. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. *Pediatr Transplant*. Dec 2004;8(6):535-542. PMID 15598320
44. Jordan SC, Vo AA, Tyan D, et al. Current approaches to treatment of antibody-mediated rejection. *Pediatr Transplant*. Jun 2005;9(3):408-415. PMID 15910400
45. Lehrich RW, Rocha PN, Reinsmoen N, et al. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. *Hum Immunol*. Apr 2005;66(4):350-358. PMID 15866697
46. Ibernón M, Gil-Vernet S, Carrera M, et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. *Transplant Proc*. Nov 2005;37(9):3743-3745. PMID 16386524
47. Gubensek J, Buturovic-Ponikvar J, Kandus A, et al. Plasma exchange and intravenous immunoglobulin in the treatment of antibody-mediated rejection after kidney transplantation: a single-center historic cohort study. *Transplant Proc*. May 2013;45(4):1524-1527. PMID 23726611
48. Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. *J Hepatol*. Jan 2016;64(1):69-78. PMID 26325537
49. Ellingsen I, Florvaag E, Andreassen AH, et al. Plasmapheresis in the treatment of steroid-dependent bronchial asthma. *Allergy*. Dec 2001;56(12):1202-1205. PMID 11736751
50. Rimmer E, Houston BL, Kumar A, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. *Crit Care*. Dec 20 2014;18(6):699. PMID 25527094

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

51. Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. *Lancet*. Oct 02 1999;354(9185):1153-1158. PMID 10513708
52. Garvey MA, Snider LA, Leitman SF, et al. Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone. *J Child Neurol*. May 2005;20(5):424-429. PMID 15968928
53. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 1.2025
54. Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. Jan 18 2011;76(3):294-300. PMID 21242498
55. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. Sep 23 2003;61(6):736-740. PMID 14504313
56. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. *J Clin Apher*. Jun 2016;31(3):149-162. PMID 27322218
57. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. *J Clin Apher*. Jul 2013;28(3):145-284. PMID 23868759
58. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., Zantek, N. D., & Dunbar, N. M. (2019, June 10). Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. *Journal of Clinical Apheresis*.
59. Glisson, C. C. (2022, May 16). Neuromyelitis optica spectrum disorders (NMOSD): Treatment and prognosis. UpToDate. From <https://www.uptodate.com>
60. Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. *J Clin Apher*. 2023;38(2):77-278. doi:10.1002/jca.22043
61. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Apheresis (therapeutic pheresis) (110.14). 1992;.

IX. POLICY HISTORY

[Top](#)

MP 4.031	04/07/2020 Consensus Review. No change to policy statement. Rationale, references and coding reviewed. FEP clarification added.
	09/01/2020 Administrative Update. New ICD-10 codes added (N00A, N01A, N02A, N03A, N04A, N05A).

MEDICAL POLICY

POLICY TITLE	PLASMA EXCHANGE (PE)
POLICY NUMBER	MP 4.031

08/09/2021 Consensus Review. No change to policy statement. References and coding reviewed.
09/07/2021 Administrative Update. Addition of new ICD-10 codes. 10/01/2021 effective date.
07/26/2022 Administrative Update. Addition of new ICD-10 codes, D59.30, 59.31, D59.32, and D59.39. Deleted D59.3. Effective 10/01/2022.
11/30/2022 Minor Review. Moved neuromyelitis optica from INV to MN. Added ICD-10 code G36.0. Updated references.
09/07/2023 Administrative Update. Addition of 11 new ICD-10 codes. Effective 10/01/2023.
12/04/2023 Consensus Review. Policy statement unchanged. Updated rationale, references. Coding reviewed, no changes. Removed M31.1.
09/03/2024 Administrative Update. Addition of 2 new ICD-10 codes, C88.00 and C88.01. Deleted C88.0. Effective 10/01/2024.
01/10/2025 Consensus Review. Policy statement unchanged. Updated references. Coding reviewed, no changes.
09/02/2025 Administrative Update. Addition of new ICD-10 codes Effective 10/01/2025
10/23/2025 Consensus Review. No change to policy statement. Updated policy guidelines and references. Removed codes N00.B and N04.B.
09/11/2026 Administrative Update. New ICD10 D69.11 added, effective 10/01/2026.

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the Blue Cross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies